The following is a summary of the Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2024 Earnings Call Transcript:

Financial Performance:

• Arcturus reported Q3 2024 revenue of $41.7 million, a slight decrease from $45.1 million in Q3 2023.

• Total operating expenses decreased to $52.4 million from $64.5 million in Q3 2023.

• R&D expenses were $39.1 million in Q3 2024, down from $51.1 million in Q3 2023.

• The company recorded a net loss of $6.9 million, improving from a net loss of $16.2 million in Q3 2023.

Business Progress:

• Arcturus launched KOSTAIVE, a self-amplifying mRNA COVID-19 vaccine, commercially in Japan.

• Positive Phase 3 results for ARCT-2303 and ongoing regulatory submissions.

• FDA clearance for a Phase 2 study of ARCT-032, an inhaled mRNA therapy for cystic fibrosis.

• Expansion of the Phase 2 clinical program for ARCT-810 (OTC deficiency) in the U.S.

• Continued development and strategic focus on mRNA therapeutics, specifically targeting respiratory illnesses and other diseases.

Opportunities:

• Expansion of manufacturing capabilities through the strategic asset Arcalis to support the future production and potential commercialization of ARCT-032 for cystic fibrosis.

Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.